Ketamine for Late-Life Depression in Older Adults

The Weight of Depression in Later Life

Depression in older adults is not the same condition it is at thirty or forty. It arrives in a different context, wears a different face, and resists treatment for different reasons.

The numbers alone are striking. Depression affects an estimated 14 to 20% of older adults living in the community. In hospital settings, prevalence climbs to 12 to 45%. In long-term care facilities, rates reach as high as 40%. These figures almost certainly undercount the problem, because late-life depression frequently presents atypically. Instead of expressing sadness, older adults may report fatigue, pain, memory problems, or simply a loss of interest in things that used to matter. Physicians screen for it less often than they should, and patients themselves may attribute their symptoms to aging rather than a treatable condition.

What makes late-life depression particularly heavy is the context it lives in. Older adults are more likely to be dealing with chronic medical conditions, chronic pain, the loss of a spouse or close friends, shrinking social networks, and diminished independence. These are not just risk factors for depression. They are ongoing realities that make depression harder to climb out of, because the circumstances feeding it do not resolve when a medication starts working.

There is also a dangerous overlap between late-life depression and cognitive decline. Depressive symptoms can mimic early dementia, and depression itself accelerates cognitive deterioration. This overlap creates diagnostic confusion and therapeutic paralysis: clinicians worry about adding medications that might worsen cognition, and patients worry that their depression symptoms mean something worse is happening.

When two or more classes of antidepressant medication fail to produce adequate relief, the condition is classified as treatment-resistant depression. This pattern is distressingly common in older adults. Their depression tends to be more chronic, more intertwined with medical illness, and less responsive to the medications that work reasonably well in younger populations.

Why Standard Antidepressants Are Harder in Older Adults

The medications we rely on for depression carry a different risk profile after age 65. Changes in liver metabolism, kidney function, body composition, and the sheer number of other medications most older adults take create a pharmacological environment where side effects are more frequent, more dangerous, and more likely to create new problems.

Consider the specific concerns with common antidepressant classes:

• SSRIs are generally the first-line treatment, but in older adults they increase fall risk through dizziness and impaired balance. Citalopram, one of the most commonly prescribed SSRIs in this population, carries a dose-dependent risk of QT prolongation, a cardiac conduction abnormality that can be fatal. SSRIs can also cause hyponatremia through a mechanism called SIADH (syndrome of inappropriate antidiuretic hormone secretion), which leads to confusion, falls, and in severe cases, seizures.
• SNRIs like duloxetine (Cymbalta) specifically increase fall risk in older adults. While duloxetine is frequently prescribed for both depression and chronic pain, the fall risk is a serious consideration in a population where a single hip fracture can trigger a cascade of disability and decline.
• Tricyclic antidepressants cause anticholinergic effects including confusion, constipation, urinary retention, dry mouth, and orthostatic hypotension (a sudden blood pressure drop upon standing that leads to falls). The American Geriatrics Society Beers Criteria explicitly flags tricyclics as potentially inappropriate for older adults.

Beyond side effects, the efficacy data for antidepressants in older adults is sobering. The OPTIMUM trial, one of the largest studies of treatment-resistant depression in older adults, tested three common strategies: augmenting an existing antidepressant with aripiprazole (29% achieved remission), augmenting with bupropion (28% remission), or switching to bupropion alone (19% remission). These are modest numbers for a population that has already failed at least one prior treatment.

Electroconvulsive therapy (ECT) remains the most effective acute treatment for severe late-life depression, with response rates above 80%. But ECT requires repeated general anesthesia, carries a risk of temporary and sometimes persistent memory impairment, involves logistical demands (transportation to and from each session, recovery time), and still faces significant stigma among patients and families. Many older adults and their families are reluctant to pursue ECT even when it is medically indicated.

The result is a treatment gap. Older adults with treatment-resistant depression are often left cycling through medications with diminishing returns and accumulating side effects, waiting for something to work well enough while their quality of life erodes.

What the Research Shows About Ketamine in Older Adults

The evidence for ketamine in late-life depression has matured considerably over the past two years. The most significant contribution is a 2025 systematic review published in the American Journal of Geriatric Psychiatry, which analyzed 13 studies encompassing 757 older adults treated with ketamine or esketamine for depression.

The review's findings were consistent across studies: ketamine and esketamine demonstrated potential efficacy for reducing depression severity in older adults, with adverse effects that were mild and transient. The most commonly reported side effects were brief dissociation, temporary increases in blood pressure, and nausea, all of which resolved within hours of the infusion.

Several individual studies within the review deserve specific attention:

• A pilot study of IV ketamine in older adults with treatment-resistant depression found a 48% response rate, with participants also showing improved executive function after treatment. That cognitive finding is particularly important and we will return to it below.
• Depression improvements persisted in over half of participants up to one month after treatment, suggesting that ketamine's effects in this population are not limited to the hours immediately following an infusion.
• No study in the review reported serious adverse events attributable to ketamine that led to treatment discontinuation in older participants.

More recently, a 2026 pilot study (KET-MCI) specifically examined whether a single IV ketamine infusion was safe and well-tolerated in older adults who had both mild cognitive impairment and depression. This was an important study because it addressed head-on the concern that many clinicians have about using ketamine in patients who already have some degree of cognitive decline. The result: no serious adverse events, and the treatment was well-tolerated.

On the mechanistic side, a March 2026 brain imaging study found that ketamine alters AMPA receptor activity in the brain, with region-specific changes that correspond to specific symptom improvements. This helps explain how ketamine works differently from traditional antidepressants: rather than slowly modulating serotonin or norepinephrine levels over weeks, ketamine rapidly changes glutamate signaling and promotes the formation of new synaptic connections.

Ketamine and esketamine show potential efficacy for late-life depression with mild transient adverse effects. Cognitive outcomes were generally stable or improved, which is a critical finding for this population. — American Journal of Geriatric Psychiatry, 2025

The Cognitive Question

If you are an older adult considering ketamine, or if you are a family member researching options for a parent or grandparent, cognition is probably the concern at the top of your list. It should be. Any treatment for depression in older adults that worsens memory or thinking is doing harm that may outweigh the benefit.

This is where the data is genuinely reassuring. Across the 13 studies and 757 patients examined in the 2025 systematic review, cognitive outcomes after ketamine treatment were generally stable or improved. No study reported lasting cognitive decline.

The pilot study that found a 48% response rate in older adults with treatment-resistant depression also assessed cognitive function before and after treatment. Participants did not just maintain their baseline cognitive abilities. They showed measurable improvement in executive function, the set of mental skills involved in planning, decision-making, and flexible thinking. This makes clinical sense: depression itself impairs executive function, and when depression lifts, cognitive performance often improves with it.

The KET-MCI study went a step further by enrolling patients who already had mild cognitive impairment alongside their depression. Even in this more vulnerable population, a single IV ketamine infusion did not worsen cognitive function.

It is worth putting this in context. Many of the standard treatments for late-life depression carry documented cognitive risks. Tricyclics cause confusion. Benzodiazepines, sometimes prescribed for the anxiety that accompanies depression, are strongly associated with cognitive impairment and increased dementia risk. Even ECT, the most effective treatment for severe depression, frequently causes temporary memory disruption that some patients find distressing. Ketamine's cognitive profile compares favorably to these alternatives.

We should note that the long-term cognitive effects of repeated ketamine infusions in older adults have not been studied in large trials. The available data covers weeks to months, not years. This is an area where ongoing research will provide important answers. But the data we have so far is encouraging rather than concerning.

Who Might Be a Good Candidate

Based on the current evidence and our clinical experience, the older adults most likely to benefit from ketamine therapy tend to share certain characteristics:

• Adults who have tried at least two antidepressant medications without adequate relief. This is the formal threshold for treatment-resistant depression, and it is the population where the evidence for ketamine is strongest.
• Patients who have experienced intolerable side effects from standard antidepressants. Falls from SSRIs, confusion from tricyclics, the cognitive fog that some patients report on multiple medication classes. Ketamine works through a different mechanism entirely and does not carry these same side effect profiles.
• Patients for whom ECT is either not an option or not desired. Whether due to medical contraindications, logistical barriers, cognitive concerns, or personal preference, many older adults need an alternative to ECT. Ketamine does not require general anesthesia and does not carry the same cognitive risks.
• Adults whose depression co-occurs with chronic pain. Ketamine has documented benefits for both depression and certain chronic pain conditions. For older adults dealing with both, this dual action can be meaningful.
• Patients who are cognitively intact or have only mild cognitive changes. The available evidence supports safety in this group. For patients with moderate to severe dementia, the data is insufficient to make recommendations, and we would not consider them candidates at this time.

Patients with uncontrolled hypertension, active psychotic symptoms, or a history of ketamine misuse would generally not be appropriate candidates. These are assessed during the initial consultation.

What to Expect at Music City Ketamine

We understand that considering a new treatment can feel uncertain, especially for older adults who may have been through years of trial and error with medications. We try to make the process as clear and comfortable as possible.

The process begins with a detailed consultation where we review your full treatment history, current medications (including blood pressure medications, blood thinners, and anything else relevant), medical conditions, and goals. For older adults, we pay particular attention to cardiovascular health, current cognitive function, fall risk factors, and potential drug interactions. This consultation is a conversation, not a sales pitch. If ketamine is not a good fit, we will tell you directly.

If we proceed, infusions are administered by Marla Peterson, CRNA, who brings more than 20 years of anesthesia experience. She monitors every session personally, tracking blood pressure, heart rate, oxygen saturation, and cardiac rhythm throughout. For older adults, this level of monitoring is particularly important because transient blood pressure increases during ketamine infusions require attentive management.

The treatment environment matters, and we have been thoughtful about it. Private rooms with comfortable recliners, soft lighting, and a calm atmosphere. Our therapy dogs, Walter White and Wilma, are often around the clinic, and many patients find their presence grounding. The space feels closer to a living room than a hospital, which tends to reduce the anxiety that accompanies any medical treatment.

Each infusion session lasts approximately 40 to 50 minutes. You will need someone to drive you to and from the appointment. Most patients feel back to their usual baseline by the following morning. We schedule initial series infusions close together, typically six sessions over two to three weeks, and then adjust the maintenance schedule based on your individual response.

Honest Expectations

We believe in giving patients accurate information rather than overpromising. Here is what the evidence supports and where uncertainties remain:

• Response is not universal. The 48% response rate in the pilot study of older adults is meaningful, but it also means roughly half of patients did not meet the threshold for clinical response. We cannot predict with certainty who will respond before treatment begins.
• The evidence base is growing but still limited. The 2025 systematic review is the most comprehensive analysis to date, but most of the included studies were small. Larger randomized controlled trials in older adults are underway but not yet published. We are making clinical decisions based on the best available evidence, which is good and getting better, but not yet definitive.
• Duration of benefit varies. Depression improvements persisted in over half of participants up to one month in the reviewed studies, but individual results range from days to months. Most patients who respond well benefit from periodic maintenance infusions.
• Insurance does not cover IV ketamine for depression. This is an out-of-pocket treatment. Sessions at Music City Ketamine are $475 each. We are upfront about this because cost is a real factor in treatment decisions, and we respect your ability to weigh that.
• Ketamine is part of a treatment plan, not the entire plan. Therapy, social connection, physical activity, sleep, nutrition, and ongoing medical care all remain important. Ketamine can provide meaningful relief from depressive symptoms, but it works best when it is part of a broader approach to wellbeing.